Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with The Surveillance Network Database - USA

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 259-263

  Sahm, Daniel F ^a   Marsilio, Mark K ^a   Piazza, Geriann ^a  

^a MRL Pharmaceutical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; METICILLIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD CULTURE; CLINICAL LABORATORY; DATA BASE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

EID: 0032801296     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520195     Document Type: Article

References (19)

1. 1. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;24:584-602.
2. 2. Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997;11:479-96.
3. 3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
4. 4. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999;29:245-52.
5. 5. Pfaller MA, Herwaldt LA. The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology. Clin Infect Dis 1997;25:858-70.
6. 6. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6: 428-42.
7. 7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: approved standard. 8th informational supplement. NCCLS document M100-S8. Villanova, PA: National Committee for Clinical Laboratory Standards, 1998.
8. 8. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.
9. 9. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
10. 10. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998;42:100-7.
11. 11. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcus infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46:626-8, 635.
12. 12. Jacoby GA. Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994;13(suppl 1):S2-11.
13. 13. Livermore DM. Are all beta-lactams created equal? Scand J Infect Dis Suppl 1996;101:33-43.
14. 14. Bush K. The evolution of beta-lactamases. Ciba Found Symp 1997;207: 152-63.
15. 15. Gaynes R, Edwards J. The National Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin resistant enterococci (VRE) in the United States, 1989-1995: the first 1000 isolates [abstract no 13]. Infect Control Hosp Epidemiol 1996;17(suppl):18.
16. 16. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
17. 17. 1996 ASCP Susceptibility Testing Group. United States geographic bacteria susceptibility patterns. Am J Clin Pathol 1998;109:144-52.
18. 18. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, Fluoroquinolone Resistance Surveillance Group. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. Diagn Microbiol Infect Dis 1994;19:203-15.
19. 19. Jacoby GA, Han P. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 1996;34:908-11.